Patient-Derived Gastric Cancer Assembloids Illuminate Stromal Impact

Study Background and Research Question

Gastric cancer remains a major clinical challenge, ranking among the most frequently diagnosed carcinomas and accounting for significant global mortality. Despite the application of surgery, chemotherapy, targeted therapy, and immunotherapy, the five-year survival rate for patients with advanced gastric cancer is still below 10%. A key contributor to poor outcomes is the marked heterogeneity of gastric tumors, particularly the complex and diverse tumor microenvironment (TME) that includes various stromal cell subpopulations. Traditional in vitro models, such as monoculture organoids or spheroids, have been limited in their ability to recapitulate this complexity, especially the influence of stromal components on tumor biology and treatment response. The primary research question addressed by Shapira-Netanelov et al. is whether a novel assembloid model, integrating both patient-matched tumor organoids and stromal cell subpopulations, can more faithfully reproduce the cellular and molecular features of human gastric tumors for translational research and drug discovery (Shapira-Netanelov et al., 2025).

Key Innovation from the Reference Study

The defining innovation of this work is the establishment of a patient-derived gastric cancer assembloid system that goes beyond standard organoid cultures. By incorporating autologous stromal cell subtypes—such as fibroblasts, mesenchymal stem cells, and endothelial cells—directly isolated from the same tumor tissue as the epithelial organoids, the assembloids achieve a high-fidelity mimicry of the TME. This system enables unprecedented investigation of the cellular cross-talk, gene expression dynamics, and drug responsiveness that occur in vivo. The approach offers a platform for studying mechanisms of drug resistance, identifying novel biomarkers, and optimizing individualized therapeutic regimens (reference study).

Methods and Experimental Design Insights

The protocol for generating gastric cancer assembloids involves several critical steps:

• Fresh tumor tissue is enzymatically and mechanically dissociated to obtain a mixed single-cell suspension.
• Distinct culture media are used to selectively expand epithelial tumor organoids, mesenchymal stem cells, fibroblasts, and endothelial cells from the same patient sample.
• These cell populations are characterized using immunofluorescence staining for lineage-specific markers to confirm identity and purity.
• Optimized co-culture conditions are established, enabling the formation of assembloids where each subpopulation maintains viability and representative functionality.
• Transcriptomic profiling (RNA sequencing) is applied to compare gene expression patterns between assembloids and monocultures.
• Drug response sensitivity is evaluated using cell proliferation and viability assays following exposure to clinically relevant agents.

This modular workflow supports the systematic evaluation of how specific stromal populations influence tumor biology, providing a versatile tool for both basic and translational cancer research.

Protocol Parameters

• Tissue dissociation: Enzymatic and mechanical digestion to obtain single-cell suspensions from fresh gastric tumor tissue.
• Cell expansion: Use of tailored growth media for organoids (epithelial), fibroblasts, mesenchymal stem cells, and endothelial cells, each optimized for selective propagation.
• Co-culture assembly: Defined ratios of tumor and stromal cells mixed in a 3D matrix under conditions supporting all populations.
• Biomarker validation: Immunofluorescence staining for epithelial (e.g., EpCAM), fibroblast (e.g., α-SMA), endothelial (e.g., CD31), and mesenchymal markers.
• Gene expression analysis: High-throughput RNA sequencing for transcriptomic profiling.
• Drug sensitivity testing: Application of chemotherapeutics or targeted agents; cell viability measured by cell proliferation assays after defined incubation periods.

Core Findings and Why They Matter

The assembloid model developed by Shapira-Netanelov et al. recapitulates the cellular heterogeneity and microenvironmental complexity of primary gastric tumors more accurately than organoid monocultures. Several key findings underscore the model's value:

• Enhanced physiologic relevance: Assembloids express a broader range of inflammatory cytokines, extracellular matrix remodeling enzymes, and tumor progression markers.
• Stromal influence on drug response: Drug screening in assembloids reveals patient- and drug-specific variability, with several agents losing efficacy in the presence of stromal components—highlighting the critical role of the TME in modulating therapeutic outcomes (Shapira-Netanelov et al., 2025).
• Insights into resistance mechanisms: The approach facilitates the identification of molecular pathways underpinning resistance to chemotherapy and targeted drugs, including those related to cell–cell interactions and extracellular matrix dynamics.
• Personalized drug screening potential: By modeling patient-specific tumor–stroma interactions, the assembloid system supports the rational design and testing of individualized treatment regimens.

These findings are significant for advancing the predictive power of preclinical models and for accelerating the translation of precision oncology strategies into clinical practice.

Comparison with Existing Internal Articles

Several recent articles have underscored the importance of robust in vitro models and precise molecular tools in studying antifolate drug resistance and tumor–stroma interactions. For example, the article "Leucovorin Calcium as a Precision Tool for Methotrexate Rescue" discusses the use of high-purity calcium folinate to dissect mechanisms of methotrexate resistance and optimize adjunct chemotherapy strategies within advanced assembloid systems. Similarly, "Leucovorin Calcium: Folate Analog for Methotrexate Rescue" details how Leucovorin Calcium enables protection from methotrexate-induced growth suppression in complex cell models, supporting translational research into folate metabolism pathways and cell viability assays. These articles complement the findings of Shapira-Netanelov et al. by providing practical guidance and experimental validation for integrating folate analogs and rescue protocols into assembloid-based workflows.

Limitations and Transferability

While the gastric cancer assembloid model presents a substantial advance over traditional organoid cultures, several limitations merit consideration. The complexity of isolating and expanding multiple autologous stromal subtypes may limit high-throughput scalability. There is also inherent variability in the proportion and behavior of stromal populations between patient samples, which could affect reproducibility across laboratories. Additionally, while the model captures many aspects of the human TME, it may not fully recapitulate immune interactions or the influence of systemic factors found in vivo. Nonetheless, the assembloid approach is broadly transferable to other cancer types where stromal heterogeneity and drug resistance are critical research questions, provided that tissue access and cell culture expertise are available.

Research Support Resources

For researchers seeking to model antifolate resistance or investigate protection from methotrexate-induced growth suppression in advanced assembloid systems, Leucovorin Calcium (SKU A2489) is a well-characterized folate analog suitable for supporting cell proliferation assays and folate metabolism pathway studies. As described in the internal literature, its high purity and defined mechanism make it a reliable choice for methotrexate rescue protocols in translational cancer models. Researchers should observe recommended storage conditions (–20°C) and use solutions promptly to ensure experimental reproducibility. For further workflow optimization and troubleshooting, detailed protocols are available in the referenced internal articles.